IL242331B - Preparation of Amorphous Taquirimate - Google Patents

Preparation of Amorphous Taquirimate

Info

Publication number
IL242331B
IL242331B IL242331A IL24233115A IL242331B IL 242331 B IL242331 B IL 242331B IL 242331 A IL242331 A IL 242331A IL 24233115 A IL24233115 A IL 24233115A IL 242331 B IL242331 B IL 242331B
Authority
IL
Israel
Prior art keywords
tecovirimat
amorphous
preparation
tecovirimat preparation
amorphous tecovirimat
Prior art date
Application number
IL242331A
Other languages
English (en)
Hebrew (he)
Original Assignee
Siga Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Tech filed Critical Siga Tech
Publication of IL242331B publication Critical patent/IL242331B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/724,7-Endo-alkylene-iso-indoles
    • C07D209/764,7-Endo-alkylene-iso-indoles with oxygen atoms in positions 1 and 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL242331A 2013-07-19 2015-10-29 Preparation of Amorphous Taquirimate IL242331B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361856240P 2013-07-19 2013-07-19
PCT/US2014/046340 WO2015009566A1 (en) 2013-07-19 2014-07-11 Amorphous tecovirimat preparation

Publications (1)

Publication Number Publication Date
IL242331B true IL242331B (en) 2021-02-28

Family

ID=52346653

Family Applications (1)

Application Number Title Priority Date Filing Date
IL242331A IL242331B (en) 2013-07-19 2015-10-29 Preparation of Amorphous Taquirimate

Country Status (8)

Country Link
US (3) US9670158B2 (https=)
EP (2) EP3763702B1 (https=)
JP (3) JP6843616B2 (https=)
CN (2) CN111635353A (https=)
AU (1) AU2014290333B2 (https=)
CA (3) CA3246369A1 (https=)
IL (1) IL242331B (https=)
WO (1) WO2015009566A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015009566A1 (en) * 2013-07-19 2015-01-22 Siga Technologies, Inc. Amorphous tecovirimat preparation
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业(石家庄)有限公司 一种奥贝胆酸片剂及其制备方法
CN112955130A (zh) * 2018-10-30 2021-06-11 佩洛通治疗公司 包含取代茚满的固体分散体和药物组合物及其制备和使用方法
CN115141136B (zh) * 2021-03-31 2023-06-20 中国人民解放军军事科学院军事医学研究院 特考韦瑞药的共晶及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011184A1 (es) 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
US6596771B2 (en) 2001-01-12 2003-07-22 Schering Corporation Drugs for treating viral infections
US6433016B1 (en) 2001-01-12 2002-08-13 Vassil Stefanov Georgiev Drugs for treating viral infections
US7687641B2 (en) 2003-06-20 2010-03-30 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
EP1638938B1 (en) * 2003-06-20 2017-04-12 Siga Technologies Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US8642577B2 (en) * 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ.ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
JP6018041B2 (ja) 2010-03-23 2016-11-02 シガ・テクノロジーズ・インコーポレーテッド St−246の多形型および調製方法
BR112012031516A2 (pt) * 2010-06-09 2016-11-08 Abbott Lab dispersões sólidas contendo inibidores de quinase
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
US8591944B2 (en) * 2011-03-08 2013-11-26 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
WO2013056108A2 (en) * 2011-10-14 2013-04-18 Array Biopharma Inc. Solid dispersion
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
CN102406617B (zh) * 2011-11-30 2013-08-28 中国人民解放军军事医学科学院生物工程研究所 一种替韦立马干混悬剂及其制备方法
WO2015009566A1 (en) 2013-07-19 2015-01-22 Siga Technologies, Inc. Amorphous tecovirimat preparation

Also Published As

Publication number Publication date
EP3021836A1 (en) 2016-05-25
EP3763702B1 (en) 2023-12-13
CA3246369A1 (en) 2025-10-30
EP3021836B1 (en) 2020-10-07
WO2015009566A1 (en) 2015-01-22
WO2015009566A8 (en) 2015-12-10
CA3128535A1 (en) 2015-01-22
JP6843616B2 (ja) 2021-03-17
CA3128535C (en) 2024-10-15
CN111635353A (zh) 2020-09-08
US9889119B2 (en) 2018-02-13
US20170224661A1 (en) 2017-08-10
AU2014290333B2 (en) 2018-11-08
JP7681393B2 (ja) 2025-05-22
EP3021836A4 (en) 2016-12-07
JP2016527229A (ja) 2016-09-08
JP2021028336A (ja) 2021-02-25
CN105307636A (zh) 2016-02-03
US20180125819A1 (en) 2018-05-10
CA2917199A1 (en) 2015-01-22
CA2917199C (en) 2021-08-31
AU2014290333A1 (en) 2015-12-03
EP3763702A1 (en) 2021-01-13
JP2023080234A (ja) 2023-06-08
US9670158B2 (en) 2017-06-06
US20160152565A1 (en) 2016-06-02
US10045963B2 (en) 2018-08-14

Similar Documents

Publication Publication Date Title
DK3689865T3 (en) Hidtil ukendte aminopyrimidinderivater
DK3088517T3 (en) Humant anti-il-33-neutraliserende monoklonalt antistof
DK3736291T3 (en) Anti-FCRH5-antistoffer
DK3354246T3 (en) Udstyrsmonteringssystem
DK3077519T3 (en) Cmv-vacciner
DK3470074T3 (en) Probiotika
DK3056208T3 (en) Immunpotentiator
AU353575S (en) Stamphousing
IL242331B (en) Preparation of Amorphous Taquirimate
GB201301329D0 (en) Fluidfoil
DK2979701T3 (en) Antitumormiddel indbefattende irinotecanhydrochloridhydrat
GB201301891D0 (en) Holo-scare
GB201301617D0 (en) T-Monitor
EP3014557A4 (en) TELEPHONE ON FILE
GB201300903D0 (en) Crystalline Form
GB201300001D0 (en) Envirep - environment replicater
AU4953P (en) Flogazora Gazania rigens
GB201310280D0 (en) Odontalgic preparation
AU353327S (en) Kettlebell
AU353330S (en) Kettlebell
AU353326S (en) Kettlebell
GB201302952D0 (en) Easily fitted longerie
AP00812S1 (en) Stumbelbloc
AU2013231V (en) Bonsca7200 Scaevola aemula
AU353341S (en) Playsuit

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed